|Day Low/High||2.57 / 2.65|
|52 Wk Low/High||2.25 / 3.89|
It's Cepheid, a small company in the running for a big government contract.
A tasty options cocktail, how to be a hit at parties and why global ETFs are overbought.
Pharmaxis shares surge after the FDA grants the company's cystic fibrosis drug fast-track status.
Because of setbacks in the company's pipeline, investors should exercise caution.
Investors need to know that its earnings and pipeline are moving in the right direction.
Shanda Interactive tanks after its fourth-quarter results fall short of estimates.
Expect the company to focus on relaunching Tysabri and extending Rituxan this quarter.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.